Table 1.
Variable | n (%) | |
---|---|---|
N | 140 | |
Age, years | Mean ± SD | 53.7 ± 13.5 |
Median (range) | 51 (25.5-86.1) | |
Menopausal status | Premenopausal | 65 (46.4) |
Postmenopausal | 75 (53.6) | |
Tumor stage | II | 50 (35.7) |
III | 90 (64.3) | |
Tumor status | T2 | 39 (27.9) |
T3 | 42 (30.0) | |
T4 | 59 (42.1) | |
Node status | N0 | 47 (33.6) |
N1 | 63 (45.0) | |
N2 | 26 (18.6) | |
N3 | 4 (2.9) | |
Tumor grade | 1 | 11 (7.9) |
2 | 63 (45.0) | |
3 | 66 (47.1) | |
ER | Positive | 87 (62.1) |
Negative | 53 (37.9) | |
PR | Positive | 68 (48.6) |
Negative | 72 (51.4) | |
Ki67 status | < 20% | 74 (42.9) |
≥ 20% | 60 (52.9) | |
Missing data | 6 (4.3) | |
HER2 | Normal | 113 (81) |
Amplification | 24 (17) | |
Missing data | 3 (2) | |
TOP2A | Normal | 124 (89) |
Amplification | 7 (5) | |
Deletion | 6 (4) | |
Missing data | 3 (2) | |
Neoadjuvant therapy | FEC75/FAC60 | 55 (39.3) |
EC-D | 85 (60.7) | |
Surgical treatment | Mastectomy | 88 (62.9) |
Lumpectomy | 52 (37.1) | |
Pathologic response | Complete | 13 (9.3%) |
Residual disease | 127 (90.7) |